Search
Research
Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy ProgramPeanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.
Research
Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 YearsRemission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor
Research
A newborn's perspective on immune responses to foodIn this review, we will highlight infants' immune responses to food, emphasizing the unique aspects of early-life immunity and the critical role of breast milk as a food dedicated to infants. Infants are susceptible to inflammatory responses rather than immune tolerance at the mucosal and skin barriers, necessitating strategies to promote oral tolerance that consider this susceptibility.
Research
Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) studyFew studies have examined long-term outcomes following oral immunotherapy; none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission).
Research
T-cell activation genes differentially expressed at birth in CD4+ T-cells from children who develop IgE food allergyTo show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.
Research
The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhoodThis study examined whether maternal and/or fetal folate status in pregnancy is associated with infant allergic outcomes.
Research
Gene polymorphisms, breast-feeding, and development of food sensitization in early childhoodThe effect of breast-feeding on the development of allergic disease is uncertain
Research
Does genetic regulation of IgE begin in utero?Elucidation of early life factors is critical to understand the development of allergic diseases, especially those manifesting in early life such as food allerg
Research
Effects of maternal dietary egg intake during early lactation on human milk ovalbumin concentration: A randomized controlled trialIncreased maternal egg ingestion is associated with increased breastmilk ovalbumin, and markers of immune tolerance in infants